InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Sustainable & Bio-Derived Injectable-Grade Excipients Market”-, By Excipient Type (Carbohydrates, Polymers & Biopolymers, Lipids & Oils, Stabilizers & Cryoprotectants, Surfactants & Emulsifiers, Others), By Source (Plant-Derived, Microbial/Biotechnological, Marine-Derived, Synthetic Bio-Derived), By Function in Formulation (Stabilizers / Protectants, Cryoprotectants / Lyoprotectants, Solubilizers & Permeation Enhancers, Controlled-Release / Depot Formers, Adjuvants for Vaccines, Bulking Agents / Fillers), By Dosage Form (Parenteral Solutions (IV, IM, SC), Lyophilized Injectables, Suspensions & Emulsions, Long-Acting Injectable (LAI) Formulations, Depot & Implantable Systems), By End-Use Application (Biologics & Biosimilars, Vaccines, Cell & Gene Therapies, Peptide & Nucleic Acid Drugs, Small Molecule Injectables)and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2035.”
Sustainable and Bio-Derived Injectable-Grade Excipients Market Size is valued at USD 1.15 Bn in 2025 and is predicted to reach USD 2.19 Bn by the year 2035 at a 6.8% CAGR during the forecast period for 2026 to 2035.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3481
Sustainable and bio-derived injectable-grade excipients are specialized formulation ingredients used in parenteral drug delivery systems, developed through environmentally responsible processes and derived from renewable biological sources. As these excipients are administered directly into the bloodstream, muscle, or tissue, they are required to meet stringent standards for safety, purity, and functional performance. Their manufacturing is aligned with green chemistry principles, emphasizing reduced carbon emissions, lower water usage, and minimized waste generation. These materials are typically obtained from plant-based feedstocks, fermentation processes, enzymatic synthesis, or recycled biological inputs, providing an alternative to conventional petrochemical-derived excipients.
Recent industry developments reflect a clear shift toward more sustainable excipient solutions. For example, in 2024, Evonik Industries introduced a bio-based synthetic polyethylene glycol (PEG) for use in injectable biologics, produced from renewable ethylene sources and designed to significantly reduce carbon emissions compared to conventional production methods.
Bio-derived excipients such as PEG, polylactic acid (PLA), and poly(lactic-co-glycolic acid) (PLGA) are increasingly utilized to improve the stability and performance of biologic therapies, including monoclonal antibodies, vaccines, and gene-based treatments. These materials play an important role in preventing protein aggregation and preserving the structural integrity of lipid nanoparticle systems used in advanced modalities such as mRNA-based vaccines.
Regulatory frameworks are also supporting this transition toward sustainable formulation components. Updated guidance from the U.S. Food and Drug Administration places greater emphasis on sustainability, safety, and biocompatibility, thereby encouraging the adoption of bio-based alternatives in pharmaceutical formulations. Consequently, there is growing utilization of biodegradable and lower-toxicity excipients, including polyvinyl alcohol (PVA) and PLGA, in alignment with broader industry sustainability objectives. This evolving landscape underscores a strategic shift toward environmentally responsible, high-performance materials within pharmaceutical manufacturing.
Read Comprehensive Report Overview: https://www.insightaceanalytic.com/report/sustainable-and-bio-derived-injectable-grade-excipients-market/3481
List of Prominent Players in the Sustainable & Bio-Derived Injectable-Grade Excipients Market:
- Nagase Viita
- Eastman Chemical Company
- Roquette Frères
- Croda International / Croda Pharma
- Evonik Industries
- Merck KGaA
- BASF SE
- ADM (Archer Daniels Midland)
- Pfanstiehl
- Ashland
- Clariant
- Actylis Lab Solutions
- CD Bioparticles
- Other Prominent Players
Market Dynamics
Drivers:
The growing demand for advanced biologic therapies—including monoclonal antibodies, vaccines, cell and gene therapies, and long-acting injectable formulations—is a major factor driving the need for high-purity, biocompatible excipients designed to meet complex stability and delivery requirements. Within this context, sustainable and bio-derived excipients provide critical functional benefits such as stabilization, cryoprotection, and controlled-release performance, making them essential components in modern pharmaceutical formulations.
In addition, increasing commitments by pharmaceutical companies to environmental, social, and governance (ESG) frameworks and net-zero emission targets are accelerating the shift toward renewable, low-carbon, and biodegradable excipient solutions derived from plant, microbial, and marine-based sources. The rapid growth of RNA-based therapeutics, including mRNA vaccines and lipid nanoparticle (LNP) delivery systems, is further strengthening demand for high-performance excipients such as sucrose, trehalose, and PEGylated lipids, with an increasing focus on sustainable and bio-based sourcing.
Challenges:
The development and commercialization of novel pharmaceutical excipients require significant financial investment, representing a key barrier to market expansion. These advanced materials involve substantial costs related to research and development, specialized manufacturing infrastructure, and regulatory compliance. Such resource-intensive requirements can pose challenges for small and mid-sized pharmaceutical companies, limiting their capacity for innovation and competitive participation. Moreover, extended development cycles associated with these excipients may delay time-to-market for new formulations.
Regional Trends:
North America is expected to maintain the largest share of the market over the forecast period, supported by the presence of major pharmaceutical companies and sustained investment in research and development activities. The region also benefits from strong collaboration across healthcare stakeholders aimed at improving disease awareness and expanding access to advanced therapeutic options. Additionally, the increasing availability of generic alternatives following patent expirations is expected to further support market growth.
In contrast, the Asia-Pacific region is projected to exhibit the fastest growth, driven by a rapidly evolving healthcare ecosystem, rising incidence of infectious diseases, and increasing demand for advanced treatment modalities. Strategic partnerships are also contributing to regional expansion. For example, in 2024, Roquette Frères partnered with Bonumose to support large-scale production of tagatose, a naturally derived sweetener with functional health benefits. This collaboration integrates enzymatic processing technologies with expertise in plant-based ingredient manufacturing, reinforcing innovation and scalability within the biopharmaceutical excipients landscape.
Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com
Recent Developments:
- In Nov 2024, Nagase Viita Co., Ltd., a member of the NAGASE Group, intends to introduce high-purity, low-endotoxin SUCROSE SG by June 2025 as part of its expansion of the SOLBIOTETM line of saccharide-based pharmaceutical excipients. In addition to TREHALOSE SG and MALTOSE PH, which are trademark products of pharmaceutical components, SOLBIOTETM’s portfolio now includes SUCROSE SG, providing a wide spectrum of stability-related options for biopharmaceutical development.
- In Oct 2023, Clariant, has announced new additions to its range of high-performing pharmaceutical ingredient solutions. To position itself as a one-stop shop for industry solutions, Clariant will introduce three new VitiPure excipients at CPHI Barcelona. These will enable a wide range of Active Pharmaceutical Ingredient (API) formulations and administration routes, including sensitive ones like mRNA vaccines and biologic medications.
Global Sustainable & Bio-Derived Injectable-Grade Excipients Market – By Excipient Type
- Carbohydrates
- Trehalose
- Maltose
- Sucrose
- Mannitol
- Sorbitol
- Polymers & Biopolymers
- Polyamino acids (PEG alternatives)
- PLA
- PLGA
- PCL
- HPMC (bio-based)
- Ethylcellulose (bio-based)
- Chitosan
- Lipids & Oils
- Plant-based squalene
- Phospholipids
- Sterols
- Stabilizers & Cryoprotectants
- Bio-derived antioxidants
- Amino Acids (glycine, arginine)
- Rice Bran Proteins
- Surfactants & Emulsifiers
- Super-refined Polysorbates
- Bio-based Lecithin
- Others (Bio-derived buffers, chelating agents, viscosity enhancers, etc)
Global Sustainable & Bio-Derived Injectable-Grade Excipients Market – By Source
- Plant-Derived
- Corn
- Sugarcane
- Soy
- Sunflower
- Algae
- Microbial/Biotechnological
- Marine-Derived
- Alginates
- Carrageenan
- Chitosan
- Synthetic Bio-Derived
Global Sustainable & Bio-Derived Injectable-Grade Excipients Market – By Function in Formulation
- Stabilizers / Protectants
- Cryoprotectants / Lyoprotectants
- Solubilizers & Permeation Enhancers
- Controlled-Release / Depot Formers
- Adjuvants for Vaccines
- Bulking Agents / Fillers
Global Sustainable & Bio-Derived Injectable-Grade Excipients Market- By Dosage Form
- Parenteral Solutions (IV, IM, SC)
- Lyophilized Injectables
- Suspensions & Emulsions
- Long-Acting Injectable (LAI) Formulations
- Depot & Implantable Systems
Global Sustainable & Bio-Derived Injectable-Grade Excipients Market – By End-Use Application
- Biologics & Biosimilars
- Vaccines
- Cell & Gene Therapies
- Peptide & Nucleic Acid Drugs
Small Molecule Injectables
Global Sustainable & Bio-Derived Injectable-Grade Excipients Market – By Region
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Customize this Study according to your Requirements @ https://www.insightaceanalytic.com/customization/3481
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
